S
68.96
-0.45 (-0.65%)
| Previous Close | 69.41 |
| Open | 69.18 |
| Volume | 2,731,853 |
| Avg. Volume (3M) | 897,000 |
| Market Cap | 11,913,322,496 |
| Price / Earnings (TTM) | 181.47 |
| Price / Earnings (Forward) | 12.32 |
| Price / Sales | 1.47 |
| Price / Book | 3.80 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2024 |
| Profit Margin | 8.76% |
| Operating Margin (TTM) | 13.06% |
| Diluted EPS (TTM) | 0.380 |
| Quarterly Revenue Growth (YOY) | 0.40% |
| Quarterly Earnings Growth (YOY) | -73.50% |
| Total Debt/Equity (MRQ) | 254.04% |
| Current Ratio (MRQ) | 1.15 |
| Operating Cash Flow (TTM) | 1.51 B |
| Levered Free Cash Flow (TTM) | 1.78 B |
| Return on Assets (TTM) | 5.75% |
| Return on Equity (TTM) | 9.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Mixed | Bearish |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | Solventum Corporation | Bullish | - |
AIStockmoo Score
-0.3
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.30 |
|
Solventum Corp is an independent healthcare company with a primary focus on addressing healthcare challenges. Its diverse product portfolio spans the healthcare industry, including medical solutions, oral care, health information systems, and separation and purification sciences. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Mid Value |
| % Held by Insiders | 19.97% |
| % Held by Institutions | 63.45% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baupost Group Llc/Ma | 30 Sep 2024 | 1,820,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 75.00 (Piper Sandler, 8.76%) | Hold |
| Median | 73.00 (5.86%) | |
| Low | 70.00 (Mizuho, 1.51%) | Hold |
| Average | 72.67 (5.38%) | |
| Total | 3 Hold | |
| Avg. Price @ Call | 71.41 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 04 Dec 2024 | 70.00 (1.51%) | Hold | 70.26 |
| Morgan Stanley | 11 Nov 2024 | 73.00 (5.86%) | Hold | 71.53 |
| Piper Sandler | 08 Nov 2024 | 75.00 (8.76%) | Hold | 72.43 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GOMEZ TAMMY L | - | 65.93 | -1,348 | -88,874 |
| Aggregate Net Quantity | -1,348 | |||
| Aggregate Net Value ($) | -88,874 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 65.93 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GOMEZ TAMMY L | Officer | 02 Jan 2025 | Disposed (-) | 1,348 | 65.93 | 88,874 |
| GOMEZ TAMMY L | Officer | 02 Jan 2025 | Option execute | 4,342 | - | - |
| Date | Type | Details |
|---|---|---|
| 08 Jan 2025 | Announcement | The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing |
| 19 Nov 2024 | Announcement | Solventum to Participate in the Piper Sandler Healthcare Conference |
| 14 Nov 2024 | Announcement | Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment |
| 07 Nov 2024 | Announcement | Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance |
| 15 Oct 2024 | Announcement | Solventum to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |